Several other brokerages have also issued reports on RETA. Zacks Investment Research lowered shares of Reata Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, September 20th. Cowen and Company began coverage on shares of Reata Pharmaceuticals in a report on Monday, June 20th. They issued an outperform rating and a $22.00 price target for the company. Finally, Citigroup Inc. began coverage on shares of Reata Pharmaceuticals in a report on Monday, June 20th. They issued a buy rating and a $32.00 price target for the company.
Shares of Reata Pharmaceuticals (NASDAQ:RETA) opened at 27.61 on Friday. The stock’s 50 day moving average price is $24.44 and its 200 day moving average price is $20.30. The company’s market capitalization is $616.39 million. Reata Pharmaceuticals has a 1-year low of $11.03 and a 1-year high of $32.22.
Reata Pharmaceuticals (NASDAQ:RETA) last announced its quarterly earnings results on Thursday, August 11th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.03. The firm earned $12.40 million during the quarter. Analysts expect that Reata Pharmaceuticals will post ($0.54) EPS for the current year.
In related news, Director Jack Nielsen bought 1,780 shares of Reata Pharmaceuticals stock in a transaction that occurred on Monday, August 22nd. The stock was purchased at an average cost of $17.00 per share, with a total value of $30,260.00. Following the purchase, the director now owns 1,780 shares in the company, valued at $30,260. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Colin John Meyer bought 7,000 shares of Reata Pharmaceuticals stock in a transaction that occurred on Tuesday, August 16th. The stock was bought at an average cost of $16.26 per share, with a total value of $113,820.00. Following the completion of the purchase, the insider now owns 27,172 shares in the company, valued at approximately $441,816.72. The disclosure for this purchase can be found here. 62.40% of the stock is currently owned by corporate insiders.
Reata Pharmaceuticals Company Profile
Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.
Receive News & Ratings for Reata Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.